| Bioactivity | Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research[1]. |
| Target | Angiopoietin-2, VEGF-A |
| Name | Faricimab |
| CAS | 1607793-29-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170. |